ArticleJournal of hematology & oncology2020
XPO1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Registry-linked trialOpen access · goldAbstract readLetter
In one paragraph
Article in Journal of hematology & oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05786989 (Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial), which is not on this map. Cited by 35 papers.
0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Selinexor Combined With R-GemOx as Second-line Treatment in Patients With Diffuse Large B-cell Lymphoma： a Single-arm, Single-centre, Open-label Trial
Who cites it
35 citing papers in PubMed, 55 citations in OpenAlex.
- Phase I/II Trial of Exportin 1 Inhibitor Selinexor plus Docetaxel in Previously Treated, Advanced KRAS-Mutant Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Preclinical characterization of a reversible XPO1 inhibitor for cancer therapy.Nature communications · 2026Article
- Targeting the nuclear export receptor exportin-1 in acute myeloid leukaemia: From biology to clinical translation.Clinical and translational medicine · 2026Review
- Targeting signaling pathways in lymphoma: From molecular mechanisms to clinical breakthroughs.Chinese medical journal · 2026Review
- A dual-mechanism model of Selinexor in DLBCL: p53 reactivation and metabolic reprogramming.Journal of translational medicine · 2026Article
- XPO1 inhibitor selinexor enhances the apoptotic effect of azacitidine in T-cell lymphoma with TET2/RHOA mutations via JAK3/STAT3 axis.Cell communication and signaling : CCS · 2025Article
- Multi-omics and experimental validation reveal mechanism of compound mylabris capsules in treating diffuse large B-cell lymphoma.Scientific reports · 2025Article
- The synergy of TPL and selinexor in MLL-R acute myeloid leukemia via Rap1/Raf/MEK pathway-mediated MYC downregulation.Translational oncology · 2025Article
- Article
- Targeting EP300 in diffuse large b-cell lymphoma: efficacy of A485 and synergistic effects with XPO1 inhibition.BMC cancer · 2025Article
- Efficacy and safety of selinexor-based regimens as first-line treatments for elderly patients with diffuse large B-cell lymphoma: a real-world study.BMC cancer · 2025Article
- Innovative evaluation of selinexor and JQ1 synergy in leukemia therapy via C-MYC inhibition.Journal of translational medicine · 2025Article
- XPO1 serves as a prognostic marker involving AKT/MAPK/TGFBR1 pathway in OSCC.Cancer medicine · 2024Article
- Beyond oncology: Selinexor's journey into anti-inflammatory treatment and long-term management.Frontiers in immunology · 2024Review
- Therapeutic targeting of nuclear export and import receptors in cancer and their potential in combination chemotherapy.IUBMB life · 2024Review
- Progress in deciphering the role of p53 in diffuse large B-cell lymphoma: mechanisms and therapeutic targets.American journal of cancer research · 2024Review
- Novel-and Not So Novel-Inhibitors of the Multifunctional CRM1 Protein.Oncology reviews · 2024Review
- The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.Scientific reports · 2023Article
- Prognostic value and therapeutic targeting of XPO1 in chronic lymphocytic leukemia.Clinical and experimental medicine · 2023Article
- Inhibition of XPO1 impairs cholangiocarcinoma cell proliferation by triggering p53 intranuclear accumulation.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 20 institutions in 9 countries.
Manman DengDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, School of Medicine, Xiamen, Fujian, China.
Mingzhi ZhangDepartment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Zijun Y Xu-MonetteDivision of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.ORCID 0000-0002-7615-3949
Lan V PhamPhamacyclics, an Abbvie Company, San Francisco, CA, USA.
Alexandar TzankovInstitute of Pathology, University Hospital Basel, Basel, Switzerland.
Carlo ViscoDepartment of Medicine, Section of Hematology, University of Verona, Verona, Italy.
Xiaosheng FangDivision of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.
Govind BhagatColumbia University Medical Center and New York Presbyterian Hospital, New York, NY, USA.
Feng ZhuDivision of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA.
Karen DybkaerAalborg University Hospital, Aalborg, Denmark.
April ChiuMayo Clinic, Rochester, MN, USA.
Wayne TamWeill Medical College of Cornell University, New York, NY, USA.
Youli ZuThe Methodist Hospital, Houston, TX, USA.
Eric D HsiCleveland Clinic, Cleveland, OH, USA.
William W L ChoiUniversity of Hong Kong Li Ka Shing Faculty of Medicine, Hong Kong, China.
Jooryung HuhAsan Medical Center, Ulsan University College of Medicine, Seoul, Korea.
Maurilio PonzoniSan Raffaele H. Scientific Institute, Milan, Italy.
Andrés J M FerreriOdense University Hospital, Odense, Denmark.
Michael B MøllerOdense University Hospital, Odense, Denmark.
Benjamin M ParsonsGundersen Lutheran Health System, La Crosse, WI, USA.
J Han van KriekenRadboud University Nijmegen Medical Centre, Nijmegen, The Netherlands.
Miguel A PirisHospital Universitario Marqués de Valdecilla, Santander, Spain.
Jane N WinterFeinberg School of Medicine, Northwestern University, Chicago, IL, USA.
Fredrick HagemeisterDepartment of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Lapo AlinariDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA.
Yong LiDepartment of Medicine, Baylor College of Medicine, Houston, TX, USA.
Michael AndreeffDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bing XuDepartment of Hematology, The First Affiliated Hospital of Xiamen University and Institute of Hematology, Xiamen University, School of Medicine, Xiamen, Fujian, China. xubingzhangjian@126.com.
Ken H YoungDivision of Hematopathology, Department of Pathology, Duke University Medical Center, Durham, NC, 27710, USA. ken.young@duke.edu.ORCID 0000-0002-5755-8932
Duke Medical Center · USOdense University Hospital · DKThe University of Texas MD Anderson Cancer Center · USAalborg University Hospital · DKAsan Medical Center · KRBaylor College of Medicine · USCleveland Clinic · USCornell University · USDuke University · USFirst Affiliated Hospital of Xiamen University · CNFirst Affiliated Hospital of Zhengzhou University · CNGundersen Health System · USMarqués de Valdecilla University Hospital · ESMayo Clinic in Arizona · USMethodist Hospital · USNewYork–Presbyterian Hospital · USNorthwestern University · USPharmacyclics (United States) · USRadboud University Nijmegen · NLSan Raffaele University of Rome · IT
Funding
Women's Cancer Research ProgramP30CA014236 · NCI · DUKE UNIVERSITY · PI DONNA NIEDZWIECKI · 1985 to 2026
$174.8MNCI NIH HHS P30 CA014236
Abstract
The XPO1 inhibitor selinexor was recently approved in relapsed/refractory DLBCL patients but only demonstrated modest anti-DLBCL efficacy, prompting us to investigate the prognostic effect of XPO1 in DLBCL patients and the rational combination therapies in high-risk DLBCL. High XPO1 expression (XPO1
Indexed as
Antineoplastic AgentsCell Line, TumorExportin 1 ProteinGene Expression Regulation, NeoplasticHumansHydrazinesKaryopherinsLymphoma, Large B-Cell, DiffusePrognosisReceptors, Cytoplasmic and NuclearTriazolesTumor Suppressor Protein p53Antineoplastic AgentsExportin 1 ProteinHydrazinesKaryopherinsReceptors, Cytoplasmic and NuclearselinexorTriazolesTumor Suppressor Protein p53BCL2DLBCLHGBCLMYCSelinexorTP53 mutationXPO1
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05786989ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.